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Thrombocytopenia isa commonphenomenon inchronicHCV infec-
tion. It has previously been linked to hepatic ﬁbrosis, portal hyper-
tension, sequestration of platelets associated with splenomegaly
and the detection of HCV-RNA in platelets of infected patients.
Previous reports by Lerat et al. (JCI 1996;97:845), de Almeira
et al. (Ann Hematology 2004;83:434 and Hepatogastroenterology
2007;54:964) and others revealed presence of HCV-RNA with
higher frequency in thrombocytopenic patients as compared to
non-thrombocytopenic individuals. This suggests that HCV is
involved directly or indirectly in the process of thrombocytope-
nia. In this issue of the Journal of Hepatology, Chai-Yen Dai
et al. conﬁrmed an association between low-platelet count and
HCV viremia in a community-based study performed in Taiwan
with 11,232 residents of whom 703 (6.2%) were anti-HCV posi-
tive. The main ﬁnding of their study is a statistically-signiﬁcant
correlation between low-platelet count (<150,000 mm3) and
qualitative detection of HCV-RNA and elevated ALT values, after
adjustment for ﬁbrosis using a FibrotTest. This signiﬁcant corre-
lation was conﬁrmed by uni- and multi-variate analysis and by
using a control group of patients with biopsy proven CLD and
chronic HCV. The authors suggest that their results support the
hypothesis that platelets may be affected directly by HCV. Indeed
this controlled study provides further indirect support for the
assumption that HCV-RNA may directly (or indirectly) suppress
formation or maturation of platelets. Yet, this putative effect still
remains a hypothesis until further information is obtained
regarding the molecular mechanism of this phenomenon.
The strength of this observation relies on the large commu-
nity-based evaluation and the methodology used for assessment.
However, as noted by the authors, the study has a number of lim-
itations since it lacks controls for a number of factors known to be
associated with thrombocytopenia in HCV including: spleen size,
portal hypertension and autoimmune-thrombocytopenia. None-
theless, this report strengthens the observation that there seems
to be an independent effect on HCV viremia on platelet count.
Further studies will be required to decipher a potential molecular
mechanism.Journal of Hepatology 20
E-mail address: Shouval@hadassah.org.ilAvoiding the pitfalls of transient hepatic elastography: the
case of congestive heart failure
Hepatic Elastography-Fibroscan (FS) and Fibrotest have cap-
tured the attention of hepatologists world wide as a non-
invasive means to assess ﬁbrosis and inﬂammatory activity,
instead of the more invasive liver biopsy. In the ongoing pro-
cess of gaining experience with these procedures, it has
become clear that despite their reported speciﬁcity and sensi-
tivity, these modalities are not always useful in some deﬁned
hepatic conditions. Case reports on false-positive results mim-
icking advanced cirrhosis have been published for FS in obese
patients with ascites, viral hepatitis, cholestasis, and congestive
heart failure.
In this issue of the Journal, Millonig and coworkers have
designed an animal model system of hepatic congestion in pigs
through clamping of the inferior and superior vena cava and
then tested the performance of FS under these conditions. They
also used their animal model to study the effect of portal vein
and hepatic artery clamping on liver stiffness. The investigators
have clearly shown that a progressive increase in intravascular
pressure in the vena cava leads to a linear and reversible
increase in liver stiffness as measured by transient elastogra-
phy; thus, mimicking stiffness measurements in cirrhosis of
the liver. They then conﬁrmed their observation in the experi-
mental model in 8/10 patients with well-deﬁned congestive
heart failure. In these patients, results of the FS were compat-
ible with the diagnosis of cirrhosis. Conventional treatment of
the underlying congestion (i.e. diuretics) leads to a decrease
in liver stiffness as measured by FS by up to 50%. The method-
ology used in the experimental animal system as well as in
humans with congestive heart failure is sound and the result
will be of value to the clinician who desires to assess the
degree of hepatic ﬁbrosis prior to therapeutic interventions
(i.e. anti-viral treatment in hepatitis C). Thus, this elegant
paper uses an experimental model to prove the concept that
congestive heart failure may lead to increased liver stiffness
mimicking cirrhosis of the liver, a situation which is reversible
by vascular declamping or pharmacological decongestion. The
obvious conclusion of this study is that prior to utilization of
the ﬁbroscan, clinicians must verify that their patients do not
have congestive heart failure and if so treat the condition prior
to performing the liver stiffness measurements.10 vol. 52 j 145–146
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Late onset ornithine transcarbamylase (OTC) deﬁciency
unmasked by the Atkins diet: an anecdotal case report or an
alert for male users of high-protein diets?
In this issue of the journal, Ben-Ari and coworkers describe a case
of hyperammonemic encephalopathy in a 47 year-old male who
started an Atkins high protein, low carbohydrate, and low fat diet
a few days prior to clinical presentation. The patient presented
with lethargy, somnolence, seizures, and encephalopathy with
radiological evidence for brain edema. Serum ammonia levels
reached 541 lg/deciliter while serum glutamine levels were
increased in the presence of low serum citrullin and secretion
of orotic acid and uracil in urine. ALT and AST were mildly ele-
vated with normal albumin and prothrombin time values. These
ﬁndings led to the tentative diagnosis of the X-linked OTC deﬁ-
ciency after ruling out systemic neurological and hepatic disor-
ders. The diagnosis of OTC deﬁciency was conﬁrmed by genetic
analysis at a later stage. A novel hemizygous missense mutation
in exon 5 was identiﬁed, which was also present in other family
members. The patient’s condition improved rapidly after treat-
ment by artiﬁcial respiration, hemodialysis low-protein diet,
administration L-arginine and sodium phenylbutirate and hyper-
alimentation with glucose and intralipid.
The urea cycle OTC deﬁciency is a relatively rare metabolic
disorder, reported mainly in neonates and young babies and146 Journal of Hepatology 201rarely in male adults. The outcome of this disorder is often fatal
in babies. In adults, it may remain asymptomatic for long periods,
even for a lifetime, but occasionally can present after ingestion of
a high-protein diet, pregnancy, or intake of certain drugs includ-
ing corticosteroids. Hepatologists and neurologists have rarely a
chance to encounter such patients. However, in recent years,
the weight reducing Atkins diet is becoming very popular in
the Western hemisphere and especially in the United States. It
is reported that one of every eleven US citizens has tried the
Atkins diets in the early 2000s. In view of the fact that OTC deﬁ-
ciency is prevalent in 1/8000–14,000 births, it is rather surprising
that until now, this metabolic disorder was not diagnosed more
frequently although concern regarding the unmasking of this
entity by the Atkins diet has been raised for some time. The ques-
tion remains open whether this is a very rare anecdotal case
report of OTC deﬁciency unmasked by the Atkins diet (and possi-
bly worsened by short-term anti-convulsant treatment with Val-
porate known to induce hyperammonemia) or indeed there are
more patients out there who consume the Atkins diet, who do
not develop the full clinical spectrum of the disease and remain
undiagnosed. Special attention may be justiﬁed in obese patients
with non-alcoholic fatty liver disease and preserved liver func-
tions who embark on an Atkins diet and develop neurological
symptoms. Thus, the purpose of presenting this case report is
to alert clinicians to this rare condition.0 vol. 52 j 145–146
